Award
NIH Reporter #5R01MH134901-03
5/5 Biomarkers to Enhance Early Schizophrenia Treatment (BEEST)
Recipient
University of California, San Diego
Award Amount
$400,000.00
Ceiling
$400,000.00
Awarded
August 31, 2026
Identifier
5R01MH134901-03
This award funds a clinical trial to improve early schizophrenia treatment using biomarker-guided decisions to enhance patient outcomes and reduce side effects.
Description
A study to determine whether biomarker-guided treatment decisions lead to better outcomes and fewer side effects in people prescribed clozapine compared to conventional antipsychotics, including changes in brain function. The study involves a multi-center, randomized clinical trial to test the use of biomarkers for improving outcomes in first episode psychosis patients.